Author:
Rehman Anees ur,Muhammad Sohail Ayaz,Tasleem Zermina,Alsaedi Alyaa,Dar Mamoona,Iqbal Muhammad Omer,Rasool Muhammad Fawad,Shah Shahid,Abbas Ghulam,Shakeel Sadia,Hayat Khezar
Abstract
AbstractChronic obstructive pulmonary disease (COPD) is associated with substantial humanistic and socioeconomic burden on patients and their caregivers. COPD is expected to be 7th leading cause of disease burden till 2030. The objective of the current study was to assess the humanistic and socioeconomic burden of COPD patients and their caregivers in Malaysia. The burden includes the cost of management of COPD, QOL of COPD patients and their caregivers, work productivity and activity impairment of COPD patients and their caregivers due to COPD. One hundred and fifty COPD patients and their caregivers from the chest clinic of Penang Hospital were included in the study from August 2018 to August 2019. Caregiving cost was estimated using the replacement cost approach, while humanistic and social burden was assessed with the help of health status questionnaires. Overall, 64.66% and 7.1% of COPD patients reported to depend on informal caregivers and professional caregivers respectively. COPD patients reported dyspnoea score as 2.31 (1.31), EQ-5D-5L utility index 0.57 (0.23), CCI 2.3 (1.4), SGRQ-C 49.23 (18.61), productivity loss 31.87% and activity impairment 17.42%. Caregivers reported dyspnoea score as 0.72 (0.14), EQ-5D-5L utility index 0.57 (0.23), productivity loss 7.19% and social activity limitation as 21.63% due to taking care of COPD patients. In addition to the huge direct cost of management, COPD is also associated with substantial burden on society in terms of compromised quality of life, reduced efficiency at the workplace, activity impairment and caregiver burden.
Publisher
Springer Science and Business Media LLC
Reference45 articles.
1. ur Rehman, A. et al. The economic burden of chronic obstructive pulmonary disease (COPD) in the USA, Europe, and Asia: Results from a systematic review of the literature. Expert Rev. Pharmacoecon. Outcomes Res. 20(6), 661–672 (2020).
2. GOLD. Global initiative for chronic obstructive lung disease (2019) https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.6-FINAL-08Nov2018-wms.pdf. Accessed 01 September 2019.
3. ur Rehman, A. et al. Pharmacological and non-pharmacological management of COPD; limitations and future prospects: A review of current literature. J. Public. Health 28(4), 357–366, (2020).
4. López-Campos, J. L., Tan, W. & Soriano, J. B. Global burden of COPD. Respirology 21(1), 14–23 (2016).
5. Rehman, A. U. et al. Assessment of risk factors responsible for rapid deterioration of lung function over a period of one year in patients with chronic obstructive pulmonary disease. Sci. Rep. 11(1), 13578 (2021).
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献